Amneal Pharmaceuticals (AMRX) Accounts Payables (2017 - 2026)

Amneal Pharmaceuticals' Accounts Payables history runs 10 years deep, the most recent figure standing at $38000.0 for Q1 2026.

• On a quarterly basis, Accounts Payables fell 99.37% year-over-year to $38000.0 in Q1 2026; TTM through Mar 2026 was $38000.0, a 99.37% decrease from a year earlier, with the FY2025 full-year figure at $55.5 million, up 228.16% from the prior year.
• Accounts Payables eased to $38000.0 in Q1 2026 per AMRX's latest filing, from $55.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $666.8 million in Q2 2025 and bottomed at $38000.0 in Q1 2026.
• The 5-year median for Accounts Payables is $11.5 million (2024), against an average of $210.2 million.
• Across the five-year window, Accounts Payables sank 99.92% in 2023 and surged 30209.86% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $863000.0 in 2022, then sank by 88.41% to $100000.0 in 2023, then soared by 16808.0% to $16.9 million in 2024, then soared by 228.16% to $55.5 million in 2025, then tumbled by 99.93% to $38000.0 in 2026.
• Per Business Quant, the three latest AMRX Accounts Payables figures stand at $38000.0 (Q1 2026), $55.5 million (Q4 2025), and $1.4 million (Q3 2025).